Schnyder U, Koller-Leiser A
Psychiatrische Poliklinik, Universitätsspital, Zürich, Switzerland.
Can J Psychiatry. 1996 May;41(4):239-44. doi: 10.1177/070674379604100409.
This study was performed to compare the clinical efficacy, side effects, and safety of paroxetine and maprotiline, the latter being the most frequently prescribed antidepressant in Switzerland.
Seventy-one patients (in and outpatients) with major depression were randomly allocated to treatment with paroxetine (20 to 40 mg daily) or with maprotiline (50 to 150 mg daily). Efficacy was measured by means of the Hamilton Psychiatric Rating Scale for Depression, the Montgomery-Asberg Depression Rating Scale, the Clinical Global Impression, and the Hopkins Symptom Checklist.
The 2 components showed a similar efficacy. The adverse effect profile was comparable in the 2 treatment groups, although the findings showed a nonsignificant trend pointing in the direction of lower side effects with paroxetine.
In the moderate dose regimens tested, the 2 components seemed to be of similar efficacy, with comparable profiles of side effects and safety.
本研究旨在比较帕罗西汀和马普替林的临床疗效、副作用及安全性，马普替林是瑞士最常处方的抗抑郁药。
71例重度抑郁症患者（包括住院和门诊患者）被随机分配接受帕罗西汀（每日20至40毫克）或马普替林（每日50至150毫克）治疗。通过汉密尔顿抑郁量表、蒙哥马利-阿斯伯格抑郁量表、临床总体印象量表和霍普金斯症状清单来衡量疗效。
两种药物显示出相似的疗效。两个治疗组的不良反应情况相当，尽管结果显示有一个无统计学意义的趋势，表明帕罗西汀的副作用较低。
在所测试的中等剂量方案中，两种药物似乎疗效相似，副作用和安全性情况相当。
